Biogen stock was slightly softer heading into the weekend, off about 0.6% on Friday and roughly flat over the past week. This signals investors were cautious rather than euphoric about this earnings print. The numbers explain why. Q2 revenue landed at US$2.7b, while basic earnings per share dropped to US$0.66 from US$2.17 in Q1, keeping the spotlight firmly on a margin squeeze that has already pulled trailing net profit margins down to 8.3% from 15.3% last year.

Is Biogen a genuine bargain at a P/E of 36.8x when the data also flags softer margins and a one off US$1.3b loss? You can compare that tension directly in our valuation analysis for Biogen

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$2,736 million vs. US$2,645.5 million (steady year on year with a slight increase)
• Net Income, Q2 2026 vs. Q2 2025: US$97.5 million vs. US$634.8 million (sharp decline in quarterly profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.66 vs. US$4.33 (material drop in earnings per share)
• Net Profit Margin, Trailing 12 Months vs. Prior Year: 8.3% vs. 15.3% (margin almost halved, reflecting a weaker profitability profile)

Prefer clear visuals instead of another dense block of Biogen earnings numbers? See Biogen's full financial picture, including a simple view of its recent profitability trend, in our company report for Biogen.

Biogen’s Growth Story: Early Proof Points, But At A Cost

Bulls argue Biogen is shifting from a concentrated multiple sclerosis and legacy base to a broader neurology and rare disease growth engine. Q2 gives some concrete proof. Growth products passed US$1b in the quarter and rose 24% year on year, with Biogen stand alone growth drugs at US$933m and up 9% year on year. That supports the claim that newer launches are steadily taking a larger share of the mix.

The Apellis acquisition is also doing what the bullish narrative expects. SYFOVRE delivered US$162m and EMPAVELI US$46m, and management now guides these assets to mid to high teens growth through 2028. At the same time, the earnings print shows the trade off for this pivot. Net income fell sharply to US$97.5m and basic EPS dropped to US$0.66, reflecting the IPR&D (in process research and development) and deal charges that come with this broader pipeline push.

Compare Biogen’s push into growth products with how institutional analysts are reacting to this earnings mix shift. See the consensus price target analysis for Biogen to gauge whether Wall Street’s targets reflect confidence in this new revenue engine or a more cautious stance.

Biogen Bears See Margin Strain, And Q2 Does Not Refute It

The bearish story around Biogen is that payer pressure, acquisition costs and pipeline bets will erode profitability faster than new drugs can support the bottom line. Q2 does not fully break that view. Revenue reached US$2.7b and the growth portfolio moved above US$1b, yet basic EPS fell to US$0.66 and trailing net margins dropped to 8.3% from 15.3%. That is exactly the margin squeeze bears worry about.

Bears also argue that deal making and portfolio reshaping would drag earnings. The Apellis acquisition and US$164m of IPR&D and milestone charges in Q2, along with guided dilution to non GAAP EPS in 2026, point in that direction. Management raised the 2026 revenue outlook and kept five Phase III readouts on the calendar. However, the near term scorecard is skewed toward higher costs and legal overhangs rather than clean operating leverage.

After EPS pressure, one-off charges and thinner margins, review whether Biogen’s issues are isolated or systemic. Expose our full risk analysis for Biogen which shows 2 important warning signs.

Guide Your Next Biogen Decision

If Biogen’s mix of margin pressure and new growth products has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry point that fits your plan. After you build a position, use the Portfolio Command Center to cut through market noise and focus on the updates that matter for your holdings. For a longer term view, tap into the Community to see how other investors are thinking about Biogen and similar stocks. This way you are set up to spot hidden catalysts and emerging risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Biogen Now

Markets move fast and the next breakout list does not stay quiet for long. Spot stocks building momentum while they are still under the radar for now and get in early.

• Scan for resilient businesses that still look priced for doubt, then work through a curated set of 56 high quality undervalued stocks before the strongest ideas get fully caught by the crowd.
• Ride structural shifts in automation and AI by checking companies already building real products. Use a focused group of 34 robotics and automation stocks to find potential early movers.
• Track copper producers as demand narratives evolve and supply stories shift. Use a targeted pool of 8 top copper producer stocks to spot setups before momentum really starts flying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.